

## **Hybrigenics and Servier reach a new step in their R&D partnership**

### **Hybrigenics to receive EUR 1.5 million milestone payment**

**Paris, 10 October 2016** – Hybrigenics (FR0004153930 - ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments of proliferative diseases, today announces a new step in its R&D partnership with Servier in the field of Ubiquitin-Specific Proteases (USPs). The research collaboration started in 2011 and has focused on one USP especially relevant to oncology. It has now reached its objectives, triggering a €1.5 million milestone payment to Hybrigenics.

Servier will take charge of the continuation of this R&D program in oncology. Hybrigenics remains associated to its success, with a total of up to €12 million further payments linked to potential additional milestones until drug registration.

Hybrigenics will intensify its own research to validate other USPs as innovative therapeutic targets and to discover new chemical series to efficiently inhibit them.

*“Thanks to its research collaboration with Servier, Hybrigenics has been able to demonstrate the interest of ubiquitin-specific proteases (USPs) in general, and of one of them in particular in oncology. We are very happy to have contributed to the discovery of inhibitors of this USP. We wish full success to Servier for the next R&D steps,”* said Rémi Delansorne, Hybrigenics’ CEO.

#### **About Hybrigenics**

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases.

Hybrigenics’ development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. Two clinical Phase II studies of inecalcitol are currently ongoing in chronic myeloid leukemia and acute myeloid leukemia.

Hybrigenics’ research program is exploring the role of enzymes called Ubiquitin-Specific Proteases (USP) in the balance between degradation and recycling of proteins called onco-proteins due to their involvement in various cancers. Hybrigenics is also evaluating the interest of inhibitors of USP as anti-cancer drug candidates. Hybrigenics has collaborated with Servier on one particular USP in oncology. In this R&D program, two steps have been reached and additional milestones may be achieved until registration of a potential drug.

Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

# HYBRIGENICS

Press Release

\*\*\*

**HYBRIGENICS is listed on the Alternext market of Euronext Paris**

**ISIN: FR0004153930**

**Ticker: ALHYG**

**ALHYG**  
**LISTED**  
**ALTERNEXT**

**Hybrigenics**

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

**NewCap**

Financial communication

Julien Perez / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.eu